Vielight’s pivotal clinical trial for Alzheimer’s Disease (AD) is set to investigate the effects of the Vielight Neuro RX Gamma device on patients with Alzheimer’s Disease. More specifically, the trial is designed to find out whether transcranial-intranasal photobiomodulation could improve cognitive functioning and quality of life in patients with moderate to severe Alzheimer’s Disease.
The participants in the study will receive Neuro RX Gamma devices for home-based treatment sessions. The Neuro RX Gamma delivers low-energy near-infrared LED light to the brain, identically to the Neuro Gamma.
This extensive study involves 228 participants in a double-blind, randomized trial and includes a placebo-controlled group. The trial will take place in 8 sites across North America. It is expected to commence in January 2019 and run till January 2021.